These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Paraneoplastic Hu and CRMP5 antibodies are present in smokers without cancer or neurological disease. Qvale TH; Storstein A; Mazengia K; Eagan TM; Bakke PS; Vedeler CA Respirology; 2014 Jul; 19(5):730-4. PubMed ID: 24697843 [TBL] [Abstract][Full Text] [Related]
8. Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review. Yan J; Chen Z; Liang Y; Yang H; Cao L; Zhou Y; Zhao Y; Zhang Y J Int Med Res; 2020 Dec; 48(12):300060520974466. PubMed ID: 33305627 [TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent. Ibrahim Ismail I; K John J; Ibrahim M; Al-Hashel JY Case Rep Neurol; 2020; 12(1):50-55. PubMed ID: 32110228 [TBL] [Abstract][Full Text] [Related]
11. Complicated paraneoplastic neurological syndromes: a report of two patients with small cell or non-small cell lung cancer. Hiasa Y; Kunishige M; Mitsui T; Kondo S; Kuriwaka R; Shigekiyo S; Kanematsu T; Satake N; Bando Y; Kondo A; Endo I; Oshima Y; Matsumoto T Clin Neurol Neurosurg; 2003 Dec; 106(1):47-9. PubMed ID: 14643918 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes. Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485 [TBL] [Abstract][Full Text] [Related]
15. [Neurologic paraneoplastic syndrome with anti-CV2/CRMP5 antibodies revealing a small cell lung cancer. Effectiveness of the lung cancer treatment]. Rosencher L; Maisonobe T; Lavole A; Milleron B; Ferroir JP Rev Neurol (Paris); 2012 Apr; 168(4):371-4. PubMed ID: 22387203 [TBL] [Abstract][Full Text] [Related]
16. [Limbic encephalitis with antibodies against intracellular antigens]. Morita A; Kamei S Brain Nerve; 2010 Apr; 62(4):347-55. PubMed ID: 20420174 [TBL] [Abstract][Full Text] [Related]
17. Predicting disability and mortality in CV2/CRMP5-IgG associated paraneoplastic neurologic disorders. Uysal SP; Li Y; Thompson NR; Milinovich A; Abbatemarco JR; Cohen JA; Conway DS; Ontaneda D; Morren JA; Kunchok A Ann Clin Transl Neurol; 2024 Mar; 11(3):710-718. PubMed ID: 38251800 [TBL] [Abstract][Full Text] [Related]
18. CV2/CRMP5-antibody-related Paraneoplastic Neurologic Syndrome Associated with Gastrointestinal Stromal Tumor. Fukushima H; Shibuya T; Awatsu T; Kurosawa T; Haga K; Murakami T; Serizawa N; Mori A; Hojo M; Yao T; Hattori N; Nagahara A Intern Med; 2022 May; 61(10):1497-1501. PubMed ID: 34670904 [TBL] [Abstract][Full Text] [Related]
19. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Jarius S; Wandinger KP; Borowski K; Stoecker W; Wildemann B Clin Neurol Neurosurg; 2012 May; 114(4):331-5. PubMed ID: 22138095 [TBL] [Abstract][Full Text] [Related]
20. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies. Fu P; He L; Tang N; Nie Q; Li Z J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]